Cubist reports Phase II data
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) reported data from Phase II trials of CXA-201 to treat complicated intra-abdominal infections (cIAIs) and CB-183,315 to treat Clostridium difficile associated diarrhea (CDAD). Cubist gained $1.07 to $34.76 on Thursday.
In 122 patients, thrice-daily IV CXA-201 plus metronidazole led to a comparable clinical cure rate at the test of cure visit 7-14 days after the end of treatment, the primary endpoint, to that of meropenem (91% vs. 94%). Cubist said the trial was not powered to assess the statistical significance of non-inferiority to meropenem. Cubist plans to start Phase III trials of CXA-201 to treat cIAIs and complicated urinary tract infections (cUTI) by year end. The company also plans to start Phase III testing of the compound to treat nosocomial pneumonia in 2012. The product is a combination of CXA-101, a cephalosporin antibiotic, and the beta lactamase inhibitor tazobactam. ...